Novo Nordisk A/S purchases B shares worth DKK 4,886 million from Novo Holdings A/S under the 2023 share repurchase programme
Novo Nordisk A/S purchases B shares worth DKK 4,886 million from Novo Holdings A/S under the 2023 share repurchase programm – Today, Novo Nordisk A/S has entered into an agreement to purchase 7,012,500 B shares of DKK 0.10 at a value of DKK 4,886 million from Novo Holdings A/S. The transaction is part of Novo Nordisk A/S’ 2023 share repurchase programme of up to a total of DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. The transaction price is DKK 696.76 per share and has been calculated as the three-day volume weighted average market price from 2 November 2023 to 6 November 2023 in the open window following the announcement of Novo Nordisk A/S’ quarterly financial results.
Prior to the sale of B shares, Novo Holdings A/S’ ownership of Novo Nordisk A/S was 28.2% of the share capital and 77.2% of the votes. Following the transaction, Novo Holdings A/S owns 1,074,872,000 A shares of DKK 0.10 and 190,183,000 B shares of DKK 0.10, corresponding to 28.1% of the capital and 77.1% of the votes in Novo Nordisk A/S.
The transaction is in line with the announcement on 1 February 2023 that Novo Holdings A/S intends to maintain its ownership of Novo Nordisk A/S’ share capital around 28%.
In addition, transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 26,194 B shares in the period from 3 November 2023 to 6 November 2023.
With the transactions stated above, Novo Nordisk A/S owns a total of 48,138,106 B shares of DKK 0.10, corresponding to 1.1% of the share capital, as treasury shares. The total number of A and B shares in the company is 4,510,000,000 of DKK 0.10 including treasury shares.
About Novo Holdings A/S
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.
Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novozymes A/S and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seeds, Venture, Growth, and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development.
As of year-end 2022, Novo Holdings had total assets of EUR 108 billion.
About Novo Nordisk A/S
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 61,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit , , , , and .
Contacts for further information
| Media: | |
| Ambre James-Brown | Elizabeth DeLuca (US) |
| Investors: | |
| Daniel Muusmann Bohsen | Jacob Martin Wiborg Rode |
| David Heiberg Landsted | Mark Joseph Root (US) |
| Sina Meyer | Frederik Taylor Pitter |
Company announcement No 71 / 2023
Attachment
